Study Backs Flu Vaccinations for Elderly
News Aug 26, 2015
A new study of the records of millions of nursing home residents affirms the value of influenza vaccination among the elderly. The Brown University analysis found that between 2000 and 2009, the better matched the vaccine was for the influenza strain going around, the fewer nursing home residents died or were hospitalized.
Although flu vaccination is a standard of care and a measure of quality in nursing homes, some public health experts question the evidence of whether they do any good, said Vincent Mor, corresponding author of the study and the Florence Pirce Grant Professor in the Brown University School of Public Health. Clinical trials that would withhold vaccination for a control group are not ethical, and observational studies that track differences among those who are vaccinated and those who are not have been suspected of bias (i.e., people left unvaccinated may be too frail compared to the vaccinated general population).
In the new research Brown public health and infectious disease experts took a different approach to assess whether vaccination helps.
Year-to-year the ability of the vaccine to fight the flu can vary widely. Sometimes vaccine makers produce a great match that is highly protective. In other years the prevailing flu strain does not match the vaccine well.
The researchers took advantage of this natural variation over the decade 2000-09 to see whether nursing home residents were better off when the match was good compared to when the match was bad. If vaccines don’t help the elderly, as some critics suggest, then nursing home residents shouldn’t fare any better when the vaccine is a good match than when it’s a bad match.
“What we’ve used is the randomness of the match,” Mor said. “Ours is the first study to, we think, come up with an unbiased approach.”
The results show that vaccinations help keep some nursing home residents alive and out of the hospital.
The match rate varied particularly widely in the flu strain A/H3N2, which is typically the strain that leads to most flu hospitalizations and deaths. Over the 10-year study period, the match rate ranged from 11.2 percent in 2003-2004 and 22 percent the next year, to 100 percent in the first two study years and in the last one. Match rates for strain A/H1N1 were usually very high and for strain B were usually low.
By comparing weekly deaths and flu-related hospitalizations in each year’s flu season, the researchers were able to calculate that for every percentage point increase in the A/H3N2 match rate, weekly deaths declined by about 0.0016 and hospitalizations declined by about 0.002 per 1,000 nursing home residents.
Those numbers may seem small, but put another way, among about 1 million elderly persons living in nursing homes each year, a 50-percentage point increase in the match rate for a flu season would save the lives of 2,560 people and prevent 3,200 hospitalizations.
“That’s saving lives,” Mor said. “That’s really a profound effect.”
Mor said the results are likely applicable to all elderly people, the vast majority of whom do not live in nursing homes. Vaccination rates among the elderly in the community, however, tend to be much lower than in nursing homes.
Co-author Dr. Stefan Gravenstein, adjunct professor of medicine and health services, policy and practice, agreed.
“This study evidences protection for an elderly population for whom vaccine efficacy has been questioned,” he said. “Annual vaccination is the only way to maximize the benefit of vaccine, no matter what the age.”
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018